Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

iBio, Inc.

NASDAQ: IBIO · Life Sciences · 6 alerts · CIK 1420720

Share price
$0.7067Close, Nov 16
Market cap
$45.4M
Shares outstanding
64.31MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All iBio, Inc. filings on SEC EDGAR ↗

4:36 PM ET 8-K
Financial Results

iBio Financial Results

iBio reported financial results for its first fiscal quarter of 2027, highlighting a revenue increase to $1.1 million compared to $0.1 million in the prior year. The company advanced its obesity pipeline, completing dosing in the SAD portion of its Phase 1 trial for IBIO-600 and presenting preclinical data for IBIO-610 showing improved fat-selective weight loss in combination with GLP-1 therapy.

Term
Q1 2027

“This was a quarter of focus and execution as we advanced our portfolio of long-acting antibody therapeutics designed to address important challenges in obesity care. The data presented at EASD strengthen our conviction in IBIO-610’s potential to deliver high-quality weight loss and provide important preclinical validation as we advance toward an IND-equivalent filing by the end of 2026, with plans to initiate first-in-human studies in the first half of 2027.”

Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.